The Global Contracting Organisation for Research, Development and Manufacturing has published its Environmental, Social and Governance (ESG) Report 2023. THE REPORT DETAILS THE COMPANY'S STRONG ESG GOVERNANCE STRUCTURE, INCLUDING A BOARD LEVEL ESG COMMITTEE, ESG STEERING GROUP, SPECIALIST DEPARTMENTS AND WORKING GROUPS. Pharma Biologics achieved steady growth in 2023, with a total of 698 integrated projects contributing to global sustainability. The company's ESG strategy aligns with the United Nations Sustainable Development Goals (SDGs) and integrates scientific ESG objectives into business operations. Pharma Biologics values diversity, equity and inclusion (DEI) and supports women in the STEM field, which employs more than 12,000 people from 56 countries. In terms of community engagement, the company's employees volunteer more than 8,000 hours, supporting rare disease projects and...Show More

The Global Contracting Organisation for Research, Development and Manufacturing has published its Environmental, Social and Governance (ESG) Report 2023. THE REPORT DETAILS THE COMPANY'S STRONG ESG GOVERNANCE STRUCTURE, INCLUDING A BOARD LEVEL ESG COMMITTEE, ESG STEERING GROUP, SPECIALIST DEPARTMENTS AND WORKING GROUPS. Pharma Biologics achieved steady growth in 2023, with a total of 698 integrated projects contributing to global sustainability. The company's ESG strategy aligns with the United Nations Sustainable Development Goals (SDGs) and integrates scientific ESG objectives into business operations. Pharma Biologics values diversity, equity and inclusion (DEI) and supports women in the STEM field, which employs more than 12,000 people from 56 countries. In terms of community engagement, the company's employees volunteer more than 8,000 hours, supporting rare disease projects and providing scholarships to rare disease students. In terms of green development, Pharmaceutical Biologics has signed the Science Basis Target Initiative (SBTi), which has reduced GHG emission intensity by 29% compared to the baseline year 2020. The company incorporates ESG concepts into an innovative platform to provide green, low-carbon solutions for drug discovery, development and manufacturing. Pharma Biologics has won multiple awards and high ESG ratings for its commitment to sustainability. The company is committed to continuing to drive technological innovation to contribute to global health and well-being. CEO DR. CHAN CHI HUNG EMPHASIZES THE COMPANY'S COMMITMENT TO ESG PRINCIPLES TO CREATE LONG-TERM VALUE FOR STAKEHOLDERS. The report also mentions initiatives in the areas of market compliance, animal welfare, sustainable supply chain management, employee development and community engagement, further cementing its position as a leader in sustainable biopharmaceutical manufacturing.